Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040045/S146

VISTAKON (SENOFILCON A) Brand Contact Lenses

Vistakon, Division of Johnson & Johnson Vision Car · Decision date Oct 8, 2026

MEDTECHLEDGER EXPLANATIONP040045/S146

What did the FDA decide?

FDA database record P040045/S146, dated 2026-10-08, is a 30-Day Notice from Vistakon, Division of Johnson & Johnson Vision Care, for VISTAKON (senofilcon A) brand contact lenses. The stated purpose is qualification of an alternate heat-sealing system in an existing manufacturing line at the Limerick, Ireland facility. The supplement type is a process change involving manufacturer/sterilizer/packager/supplier, and the decision field reads OK30.

This notice does not represent a new approval of the underlying device system. The identifier links the supplement to original PMA P040045, but the record does not state that the alternate heat-sealing system was independently proven safe or clinically effective. The source statement reports only the intended qualification; it does not describe testing results, acceptance criteria, or any change to indications, labeling, or clinical performance. Specific information about the qualification outcome is absent from the provided fields.

FDA approval order statement

qualification of an alternate heat-sealing system in an existing manufacturing line to produce VISTAKON (senofilcon A) contact lenses, at the manufacturing facility located in Limerick, Ireland
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 8, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P040045/S146
Regulatory pathway
PMA supplement
Product code
LPM
Decision code
OK30
Decision date
Oct 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lenses, soft contact, extended wear.

Product code
LPM
FDA device class
3

For the original device and its historical approval scope, see PMA P040045. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P040045 · Original PMA

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  2. P040045/S145 · Related supplement

    VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER

  3. P040045/S146 received

    Application receipt date recorded by FDA.

  4. P040045/S146 · FDA decision

    30-Day Notice

  5. P040045/S147 · Related supplement

    VISTAKON (senofilcon A) Brand Contact Lenses

Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040045

Explore the linked device profile

Other records with product code LPM

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch and Lomb, Inc.,PMA supplementSep 14, 2026FDA
CooperVision, Inc.PMA supplementSep 2, 2026FDA
Bausch and Lomb, Inc.,PMA approvalApr 30, 2018FDA
CooperVision, Inc.PMA approvalNov 19, 2008FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Vistakon, Division of Johnson & Johnson Vision Car

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records